| Ticker Details |
Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company. It discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases.
|
| IPO Date: |
December 7, 2000 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$536.75M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.24 | 2.82%
|
| Avg Daily Range (30 D): |
$0.75 | 2.48%
|
| Avg Daily Range (90 D): |
$0.66 | 2.10%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.9M |
| Avg Daily Volume (30 D): |
.34M |
| Avg Daily Volume (90 D): |
.29M |
| Trade Size |
| Avg Trade Size (Sh.): |
200 |
| Avg Trade Size (Sh.) (30 D): |
52 |
| Avg Trade Size (Sh.) (90 D): |
48 |
| Institutional Trades |
| Total Institutional Trades: |
1,885 |
| Avg Institutional Trade: |
$1.44M |
| Avg Institutional Trade (30 D): |
$1.43M |
| Avg Institutional Trade (90 D): |
$1.54M |
| Avg Institutional Trade Volume: |
.04M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.65M |
| Avg Closing Trade (30 D): |
$1.54M |
| Avg Closing Trade (90 D): |
$1.64M |
| Avg Closing Volume: |
56.65K |
|
|
| Financials |
| |
TTM |
Q1 2026 |
Q4 2025 |
|
Basic EPS
|
$20.23
|
$.47
|
$14.88
|
|
Diluted EPS
|
$19.28
|
$.44
|
$14.1
|
|
Revenue
|
$299.77M
|
$58.82M
|
$69.8M
|
|
Gross Profit
|
$279.95M
|
$54.21M
|
$63.85M
|
|
Net Income / Loss
|
$364.23M
|
$8.65M
|
$268.07M
|
|
Operating Income / Loss
|
$124.58M
|
$11.89M
|
$23.17M
|
|
Cost of Revenue
|
$19.82M
|
$4.61M
|
$5.96M
|
|
Net Cash Flow
|
$-21.32M
|
$-16.17M
|
$-7.95M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Jun 27, 2024
|
1:10
|
|
Jun 25, 2003
|
1:9
|
|
|
|
